Skyrizi (risankizumab-rzaa), an interleukin-23 inhibitor, has received U.S. Food and Drug Administration approval to treat moderately to severely active Crohn disease (CD) in adults, according to AbbVie.
Jun 20, 2022
0
4
The virus that causes COVID-19 can develop partial resistance to the antiviral drug remdesivir during infection of cultured cells in the laboratory by more than one mechanism.
May 4, 2022
0
107
Purdue University researchers in the College of Pharmacy and College of Engineering are developing a patent-pending treatment that could impact millions of American lives each year.
Apr 25, 2022
0
803
Chemotherapy is known for its painful side-effects. It also has limitations when the cancer has metastasized to the lymph nodes. The lymphatic drug delivery system, where anticancer drugs are injected directly into the sentinel ...
Mar 29, 2022
0
6
A gene-silencing therapy protected against Zika virus transmission from pregnant mice to the mouse fetuses, finds a study published November 10th in the journal Molecular Therapy. The treatment, which harnesses nanoparticles ...
Nov 10, 2021
0
22
Researchers at LKS Faculty of Medicine, The University of Hong Kong (HKUMed) and collaborators from the School of Basic Medical Sciences, Fudan University, Shanghai, have developed an 'intravenous injection plus light-triggered ...
Aug 30, 2021
0
230
Patients with tuberous sclerosis complex, a genetic disorder characterized by the growth of noncancerous tumors in multiple organs of the body, have limited treatment options. A team led by investigators at Massachusetts ...
Jan 9, 2021
0
124
TXA, a drug that prevents severe bleeding after injury by inhibiting blood clot breakdown, is most effective when given soon after injury. Every 15 minutes treatment delay reduces its lifesaving potential by 10%. However, ...
Oct 1, 2020
0
2
A meta-analysis of non-human primate (NHP) studies showed that adeno-associated virus (AAV) gene therapy often caused dorsal root ganglion (DRG) pathology. There were no clinical effects. The study is reported in the peer-reviewed ...
Sep 2, 2020
0
2
(HealthDay)—Tauvid (flortaucipir F18), a radioactive diagnostic agent, was approved to image tau pathology in patients with cognitive impairment being evaluated for Alzheimer disease, the U.S. Food and Drug Administration ...
Jun 2, 2020
0
0
